StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Direct Clinical R&D by Quarter

Direct Clinical R&D — EYLEA HD (aflibercept 8 mg) ($M) ($M)

Regeneron Pharmaceuticals Direct Clinical R&D: $16.5M in Q4 2025, down 26.0% from a year earlier.

Latest, Q4 2025
16.5
Period ended Dec 31, 2025
Change on a year earlier
-26.0%
22.3 in Q4 2024
History
16 quarters
Since Q1 2022
Sources
12
Documents cited below

Where the Q4 2025 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗

Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDirect Clinical R&D — EYLEA HD (aflibercept 8 mg) ($M) ($M)Year on yearSource
Q4 2025Dec 31, 202516.5-26.0%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202521.1-27.0%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2025Jun 30, 202522.6-10.0%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2025Mar 31, 202530.3+38.4%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 202422.3-8.2%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2024Sep 30, 202428.9+57.9%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 202425.1-10.0%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 202421.9-14.8%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202324.3+4.3%Form 10-K (regn-20251231.htm; 0001804220-24-000040|regn-20240930.htm, filed 2026-02-04) ↗
Q3 2023Sep 30, 202318.3+69.4%Form 10-Q (regn-20240930.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202327.9+105.1%Form 10-Q (regn-20240630.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 202325.7+27.2%Form 10-Q (regn-20240331.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 202223.3–Form 10-K (regn-20241231.htm; 0001804220-23-000031|regn-20230930.htm, filed 2025-02-05) ↗
Q3 2022Sep 30, 202210.8–Form 10-Q (regn-20230930.htm, filed 2023-11-02) ↗
Q2 2022Jun 30, 202213.6–Form 10-Q (regn-20230630.htm, filed 2023-08-03) ↗
Q1 2022Mar 31, 202220.2–Form 10-Q (regn-20230331.htm, filed 2023-05-04) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Direct Clinical R&D ($M), quarterly Q1 2022–Q4 2025 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-eylea-hd

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?